Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04178460
Other study ID # ZL-2306-006
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date February 3, 2020
Est. completion date March 2, 2022

Study information

Verified date May 2022
Source Zai Lab (Hong Kong), Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a a Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination with MGD013 in Patients with Advanced or Metastatic Solid Tumor Who Failed Prior Treatment. This study consists of dose escalation part and dose expansion part.'3+3'design will be adopted in the dose escalation part in subjects with advanced or metastatic gastric cancer who failed prior treatment. The dose of niraparib will be fixed and determined based on baseline weight and platelet count of subjects. Dose expansion part will be expanded at the specified dose level to further assess the safety and preliminary antitumor activity.


Recruitment information / eligibility

Status Terminated
Enrollment 60
Est. completion date March 2, 2022
Est. primary completion date March 2, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: 1. Signed written informed consent form. 2. = 18 years old. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. 4. Subjects who have at least one measurable lesion according to RECIST v1.1 criterion (only applicable for subjects at dose expansion part). 5. Subjects with adequate organ function. 6. Subjects with life expectancy of 12 weeks or more. Inclusion criteria for different indications: Dose escalation part and EXP-1 gastric cancer (including gastroesophageal junction cancer) 1. Subjects with histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; 2. Subjects who have previously failed at least 2 prior systemic treatment for locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; treatment failure is defined as the occurrence of disease progression or intolerable adverse events during treatment. Subjects who have progressed on first-line chemotherapy with platinum and fluoropyrimidine for advanced disease, and who are deemed unfit/ineligible for further chemotherapy or anti-angiogenesis therapy may also be eligible; EXP-2 triple negative breast cancer (TNBC) 1. Subjects with metastatic or inoperable locally advanced, histologically documented TNBC characterized by absence of human epidermal growth factor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) expression based on most recently analyzed biopsy or archived tissue; 2. Subjects with disease progression or relapse after = 2 prior lines of standard chemotherapy regimens in the locally advanced or metastatic disease stage (if the disease is progressed to unresectable locally advanced or metastatic disease within 12 months after adjuvant or neoadjuvant chemotherapy for limited-stage disease, it can be counted as 1 prior line); 3. Subjects with LAG-3 expression meeting the criteria of moderate or high expression (confirmed by the central laboratory); 4. Subjects who have undergone prior taxane therapy regardless of disease stage (adjuvant, neoadjuvant, or advanced) at the time of treatment; or subjects who are not eligible for taxane therapy because of contraindications; EXP-3 biliary tract carcinoma 1. Subjects with histologically confirmed, surgically unresectable locally advanced, recurrent or metastatic biliary track carcinoma (BTC), including cholangiocarcinoma or gallbladder carcinoma; 2. Subjects with disease progression or relapse after = 1 prior standard chemotherapy regimen. If the patient received preoperative neoadjuvant chemotherapy or adjuvant chemotherapy after R0 radical resection, and the disease progression occurred during the chemotherapy or within 6 months after discontinuation of chemotherapy, it may be counted as first-line treatment failure; 3. Subjects with LAG3 expression meeting the criteria for moderate or high expression (confirmed by the central laboratory); 4. Subjects without known IDH-1 mutations or FGFR2 fusions (if status is unknown, the subject will be included without the need for active testing). EXP-4 endometrial carcinoma 1. Subjects with histologically confirmed advanced or metastatic endometrial carcinoma; 2. Subjects with disease progression or relapse after = 1 prior standard chemotherapy regimen in the advanced or metastatic stage; 3. Subjects with LAG-3 expression meeting the criteria for moderate or high expression (confirmed by the central laboratory); 4. Subjects without carcinosarcomas, endometrial leiomyosarcomas, or other high-grade sarcomas, or endometrial stromal sarcomas. Exclusion criteria: 1. Known hypersensitivity to niraparib or active or inactive ingredients of drugs with similar chemical structure to niraparib. 2. Subjects who have previously received PARP inhibitors (including niraparib) treatment; anti-LAG-3 treatment. 3. Subjects who have received treatment with other investigational drugs within 4 weeks prior to the first dose of study drug or < 5 elimination half-lives of the investigational drug (whichever is longer); subjects who have underwent a major surgery within 4 weeks prior to the start of study, or with any surgical side effects that have not been recovered. 4. Subjects who experienced = Grade 3 anemia, neutropenia or thrombocytopenia due to prior chemotherapy, which lasted more than 4 weeks. 5. Subjects who experienced transfusion dependent anemia or thrombocytopenia, including: - Blood (platelet or red blood cell) transfusion within 2 weeks prior to the first dose; - Subjects who previously received colony stimulating factor treatment (e.g., granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF) or recombinant erythropoietin) within 2 weeks prior to the first dose. 6. Untreated or symptomatic brain metastases or leptomeningeal metastases (e.g., new or worsening symptoms or vital signs, or unstable dose of hormones required). Note: There is no need for the imaging scan to confirm absence of brain metastases; subjects with spinal cord compression who have previously received definitive therapy and have an evidence for clinically stable disease at least > 28 days can be enrolled. 7. Subjects who have received palliative radiotherapy on > 20% bone marrow area within 3 weeks prior to enrollment. 8. Subjects who have other invasive cancers (except treated in situ cancer, non-melanoma skin cancer, localized prostate cancer (Gleason score < 6), etc.) other than gastric cancer, endometrial carcinoma, biliary tract carcinoma and breast cancer within 5 years prior to enrollment. 9. Subjects who have been previously or are currently diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). 10. Subjects who have severe or uncontrolled diseases, including but not limited to: - Digestive tract hemorrhage within 2 months prior to enrollment or currently active digestive tract hemorrhage; - Uncontrolled nausea and vomiting, inability to swallow the investigational drugs, or any gastrointestinal diseases that may intervene with and influence drug absorption and metabolism; - Human immunodeficiency virus (HIV) infection, active hepatitis (e.g., hepatitis B (HBV-DNA > 500 IU/ml), hepatitis C virus ribonucleic acid (HCV-RNA) positive); - Uncontrolled ventricular arrhythmia, myocardial infarction that occurred within 3 months prior to enrollment; - Uncontrolled grand mal seizure, unstable spinal cord compression, superior vena cava syndrome or other mental disorders influencing subjects to sign informed consent forms; - Immunodeficiency (except splenectomy). 11. Subjects with known or suspected history of autoimmune disease, except: vitiligo and psoriasis that does not require systemic treatment (in recent two years); subjects with a history of Grave's disease that are now euthyroid clinically and by laboratory testing. 12. Treatment with systemic corticosteroids (= 10 mg/day prednisone or equivalent) or other immunosuppressive drugs within 14 days prior to the initiation of the study treatment. 13. If patients who have previously used immune checkpoint inhibitors (such as anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies) have the following adverse events related to immune checkpoint inhibitors, they will be not suitable for inclusion regardless of recovered or not: - = Grade 3 eye-related adverse events; - Abnormal hepatic function met Hy's Law criteria; - = Grade 3 neurotoxicity; - = Grade 3 colitis; - = Grade 3 renal toxicity. 14. Subjects with a history of pneumonitis requiring steroid treatment or current pneumonitis. 15. Subjects with previous or current disease, treatment, or laboratory abnormality that may intervene with study results and affect subjects participating in the study, or subjects not suitable for participation in the study at the investigator's discretion.

Study Design


Intervention

Drug:
Niraparib combined with MGD013
The dose escalation part will enroll about 9 - 24 Gastric cancer (including gastroesophageal junction cancer) subjects, with fixed dose niraparib (200mg or 300mg) combined with MGD013 (120mg, 300mg or 600mg ) in different dose level. For the dose expansion part, patients with advanced or metastatic Gastric cancer (including gastroesophageal junction cancer), Triple negative breast cancer, Biliary tract carcinoma, Endometrial carcinoma will be enrolled, about 35 subjects for each expansion cohort during dose expansion phase with fixed dose niraparib (200mg or 300mg) combined with fixe dose MGD013 (to be confirmed after dose escalation).

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing
China Beijing Cancer Hospital Beijing
China Sichuan Cancer Hospital Chengdu Sichuan
China Sun Yat-Sen University Cancer Center Guangzhou
China Sun Yat-Sen University Cancer Center Guangzhou Guangdong
China The Affiliated Tumor Hospital of Harbin Medical University Ha'erbin
China The First Affiliated Hospital Zhejiang University School Of Medicine Hangzhou Zhejiang
China The Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong
China The University of Hong Kong, Queen Mary Hospital Hong Kong
China Obstetrics & Gynecology Hospital of Fudan University Shanghai Shanghai
China Liaoning Cancer hospital Shenyang Liaoning
China Taizhou Hospital of Zhejiang Province Taizhou
China TianJin Medical University General Hospital Tianjin Tianjin
China Hubei Cancer Hospital Wuhan Hubei
China Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology Wuhan
China First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi
China Sir Run Shaw Hospital, School Of Medicine ,Zhejiang University Zhejiang
China Henan Cancer Hospital Zhengzhou Henan
China Henan Cancer Hospital Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
Zai Lab (Shanghai) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and Validity profiles Phase I Dose Escalation Part:
To determine the dose-limiting toxicity (DLT) and maximal tolerated dose (MTD) of niraparib in combination with MGD013 in patients with advanced or metastatic gastric cancer;
To determine the recommended phase II dose (RP2D) of niraparib in combination with MGD013 in patients with advanced or metastatic solid tumors.
approximately 45months
Primary Validity profiles Phase I Dose Expansion Part:
ā€¢ To assess the objective response rate (ORR) of niraparib in combination with MGD013 in patients with different types of advanced or metastatic solid tumors.
approximately 45months
Secondary Safety and Validity profiles Phase I Dose Escalation Part:
To assess the safety and tolerability of different doses levels of niraparib in combination with MGD013 in patients with advanced or metastatic gastric cancer;
To assess the preliminary antitumor activity of niraparib in combination with MGD013 in patients with advanced or metastatic gastric cancer, including objective response rate (ORR), disease control rate (DCR), etc.
approximately 45months
Secondary Safety and Validity profiles Phase I Dose Expansion Part:
To assess other antitumor activity of niraparib in combination with MGD013 in patients with different types of advanced or metastatic solid tumors, including duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), time to tumor progression (TTP), and overall survival (OS);
To assess the safety and tolerability of niraparib in combination with MGD013 in patients with different types of advanced or metastatic solid tumors.
To assess the antitumor activity of niraparib in combination with MGD013 in patients with different HRR gene status, expression level of PD-L1 and LAG-3.
approximately 45months
Secondary Exploratory objective To explore the correlation between other biomarkers related to MGD013/niraparib and subject safety, antitumor activity. approximately 45months
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabineļ¼¸Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2